Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 153Lymphoid 136Myeloid 5Sarcoma 3Tumor-Agnostic 2CNS 2Other 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Glioblastoma 2Rare Diseases 1Oligodendroglioma 1Neoplasms 1Glioma 1Genetic Diseases, Inborn 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Mercaptopurine × CNS × Clear all
NCT06279767 2024-02-28

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Unknown
27 enrolled
CNS

Glioblastoma, Neoplasms

NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡